Donnelly Brian J 4

What Happened

• Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics (MYGN), acquired 5,000 shares on 2026-06-11. The shares were purchased at $3.94 per share for a total cost of $19,680. The transaction is reported on a Form 4 filed 2026-06-12.
• This was an acquisition through the issuer’s Employee Stock Purchase Plan (ESPP), not a sale. Purchases by insiders are often considered more informative than sales, though no motivation should be assumed.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely).
• Transaction type/code: A — Grant, award or other acquisition.
• Shares acquired: 5,000 at $3.94 per share; total value: $19,680.
• Footnote: Shares were acquired under the Issuer’s Amended and Restated 2012 Employee Stock Purchase Plan; exempt under Rule 16b-3(d) and 16b-3(c).
• Shares owned after the transaction: not specified in the provided filing details.

Context

• The acquisition was via an ESPP, a common way employees purchase company stock, often at a discount or via payroll deductions. The filing’s exemption language reflects standard Rule 16b-3 treatment for ESPP purchases by insiders.